GGrantIndex
← Search

Molecular Imaging (Program 2)

$7,090P30FY2018CANIH

Wayne State University, Detroit MI

Investigators

Linked publications, trials & patents

Trial NCT06501040Trial NCT04479267Trial NCT04397679Trial NCT04266522Trial NCT04159896Trial NCT03875053Trial NCT03683420Trial NCT03456804Trial NCT03454529Trial NCT03453489Trial NCT03406858Trial NCT03252600Trial NCT03147885Trial NCT02824029Trial NCT02819024Trial NCT02723604Trial NCT02620865Trial NCT02568449Trial NCT02521090Trial NCT02520115Trial NCT02472275Trial NCT02470559Trial NCT02359019Trial NCT02178436Trial NCT02178163Trial NCT02173093Trial NCT02145078Trial NCT02094872Trial NCT02058706Trial NCT02037256Trial NCT01987596Trial NCT01958372Trial NCT01698658Trial NCT01504711Trial NCT01281163Trial NCT01175980Trial NCT01147016Trial NCT01116232Trial NCT01071564Trial NCT01051570Trial NCT01022138Trial NCT00984919Trial NCT00972023Trial NCT00942422Trial NCT00938626Trial NCT00935090Trial NCT00918762Trial NCT00914147Trial NCT00906503Trial NCT00903214Trial NCT00899665Trial NCT00897910Trial NCT00897741Trial NCT00897494Trial NCT00897247Trial NCT00890617Trial NCT00888654Trial NCT00769288Trial NCT00768118Trial NCT00717535Trial NCT00691015Trial NCT00559897Trial NCT00541099Trial NCT00527124Trial NCT00521261Trial NCT00520767Trial NCT00514215Trial NCT00503841Trial NCT00499694Trial NCT00482846Trial NCT00459121Trial NCT00438204Trial NCT00423826Trial NCT00410904Trial NCT00376948Trial NCT00369109Trial NCT00305747Trial NCT00303901Trial NCT00301808Trial NCT00293384Trial NCT00288028Trial NCT00258466Trial NCT00258310Trial NCT00258284Trial NCT00258245Trial NCT00258232Trial NCT00248560Trial NCT00248482Trial NCT00244946Trial NCT00244933Trial NCT00243048Trial NCT00238329Trial NCT00227721Trial NCT00217581Trial NCT00121264Trial NCT00118157Trial NCT00078923Trial NCT00068653Trial NCT00066326Trial NCT00056004

Abstract

ABSTRACT The goals of the Molecular Imaging (MI) Program include the development and testing of new imaging methods ranging from preclinical work on the synthesis of new probes and development of new devices to the clinical evaluation of imaging approaches to assess cancer risk, detect cancer, guide treatment and monitor therapy. These imaging methods are aimed at improving our understanding of cancer physiology and using these findings to ultimately improve the assessment of cancer and its treatment. This highly interactive Program includes 19 members from 8 WSU departments and $5,173,403 in grants, of which $2,626,204 is peer reviewed. We have two themes to achieve Program goals. The first theme is to synthesize and develop new methods to image tumor metabolism and drug pharmacodynamics. Optical methods are being explored for the development of in vitro and in vivo models to image tumor metabolism and treatment responses. This work includes the development of new tracers for Positron Emission Tomography (PET) to measure tumor pathways, predict drug activity, assess drug delivery using labeled agents and monitor treatment response. New magnetic resonance (MR) and spectroscopic techniques, which measure metabolism, include the synthesis of new probes, the application in preclinical studies and incorporation into clinical trials. The second theme involves implementing and testing these new imaging methods for risk assessment, detection, guidance and assessment of the response to therapy. It incorporates the development of new ultrasound tomographic (UST) imaging of the breast for use in assessment of risk associated with breast density, as well as tumor detection and treatment response and the role these approaches can play in decreasing health disparities. The evaluation of new and standard PET probes is underway, including studying their use with pilot trials of targeted treatments and large scale studies leading to national approval of PET approaches. New methods to deliver, direct and monitor radiation therapy are also underway. MI Program members actively collaborate with members of the MT, TBM, and PSDR Programs at KCI. Of the 358 manuscripts published from December 2010 to November 2014, 33% were intra-programmatic and 34% were inter-programmatic, and 26% were multi-institutional collaborations.

View original record on NIH RePORTER →
Molecular Imaging (Program 2) · GrantIndex